Antimicrobial stewardship enhancing the submission rate of microbiological specimens before therapeutic use of antimicrobial agents

doi:10.16150/j.1671-2870.2019.01.019

Abstract

Abstract:

Objective: To investigate the effect of antimicrobial stewardship（AMS） on enhancing submission rate of microbiological specimens before therapeutic use of antimicrobial agents. Methods：January 2017 to June 2017 was the pre-intervention group; July 2017 to September 2017 was the post-intervention group. Submission rate of microbiological specimens before therapeutic use of antimicrobial agents were compared between the two groups. Constituent ratio of different microbiological specimens was also compared between the two groups. Results: The submission rates of microbiolo-gical specimens for general, restricted and special therapeutic use of antimicrobial agents before and after AMS increased from 49.46%, 47.82%, 69.91% to 61.94%, 62.11%, 83.45%, respectively (P all <0.01). The submission rate of microbiological specimens for general and special therapeutic use of antimicrobial agents before and after AMS in key departments reached the assessment criteria.The constituent ratio of sputum culture specimen was decreased from 53.46% to 51.66%( P<0.01), and the constituent ratio of blood culture and aseptic humoral specimen increased from 11.96% and 3.60% to 15.32% and 4.10%(P<0.01, P<0.05). Conclusions: AMS can effectively improve the submission rate of microbiological specimens before therapeutic use of antimicrobial agents and the quality of specimens for inspection; it provides laboratory evidence for the rational use of antibiotics.

Key words: Antimicrobial stewardship, Submission rates of microbiological specimen, Blood culture, Sputum culture, Aseptic humoral culture

CLC Number:

R372

WU Hao, FANG Hua, WANG Ruizhong, QU Jinghua, SHEN Xiaofeng, CHEN Huaping, GU Wenchao. Antimicrobial stewardship enhancing the submission rate of microbiological specimens before therapeutic use of antimicrobial agents[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 93-97.

Figures/Tables 4

References 15

[1]	Reed EE, Stevenson KB, West JE, et al. Impact of formulary restriction with prior authorization by an antimicrobial stewardship program[J]. Virulence, 2013, 4(2):158-162.
[2]	Chahine EB, El-Lababidi RM, Sourial M. Engaging Pharmacy Students, Residents, and Fellows in Antimicrobial Stewardship[J]. J Pharm Pract, 2015, 28(6):585-591.
[3]	Shlaes DM. Role of Antimicrobial Stewardship in Prevention and Control of Antibiotic Resistance[J]. Curr Infect Dis Rep, 1999, 1(4):334-337.
[4]	杨婧, 杨蕾, 刘姗, 等. 选择式目标管理提高临床微生物标本送检率[J]. 中国感染控制杂志, 2015, 14(5):342-343.
[5]	《抗菌药物临床应用指导原则2015版》(国卫办医发〔2015〕43号)[EB/OL]. http://www.nhc.gov.cn/yzygj/s3593/201508/c18e1014de6c45ed9f6f9d592b43db42.shtml.
[6]	《关于进一步开展全国抗菌药物临床应用专项整治活动的通知》(卫办医政发〔2013〕37号)[EB/OL]. http://www.nhc.gov.cn/yzygj/s3585u/201305/823b9d131ff4416ab7b41b2c4e1f0e83.shtml.
[7]	Dixon J, Duncan CJ. Importance of antimicrobial stewardship to the English National Health Service[J]. Infect Drug Resist, 2014, 7:145-152.
[8]	Lew KY, Ng TM, Tan M, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting[J]. J Antimicrob Chemother, 2015, 70(4):1219-1225.
[9]	韩冰, 隋忠国, 李祥鹏, 等. 48家医疗机构抗菌药物管理体系建设情况分析[J]. 中国执业药师, 2016, 13(9):40-44.
[10]	赵泉, 王颖琳, 张雷, 等. 某三级甲等医院抗菌药物科学化管理实践与思考[J]. 中国药业, 2017, 26(18):92-94.
[11]	宋珍, 黄卫春, 顾飞飞, 等. 住院肺炎患儿呼吸道标本分离菌及其耐药性分析[J]. 诊断学理论与实践, 2016, 15(4):421-425.
[12]	刘波, 张卫红, 李松琴, 等. 提高微生物标本送检率的临床效果评价[J]. 中国感染控制杂志, 2016, 15(11):862-864.
[13]	殷俊, 常啸, 程君, 等. 安徽省某三甲医院铜绿假单胞菌分布及耐药特点研究[J]. 安徽医学, 2018, 39(9):1088-1090.
[14]	胡付品, 郭燕, 朱德妹, 等. 2016年中国CHINET细菌耐药性监测[J]. 中国感染与化疗杂志, 2017, 17(5):481-491.
[15]	林佳冰, 高晓东, 崔扬文, 等. 上海市90所医院临床病原学标本送检及耐药菌检出现状分析[J]. 中华医院感染学杂志, 2018, 28(8):1162-1165.

方法	治疗性使用抗菌药物前微生物标本总送检率			接受限制使用级抗菌药物前微生物标本送检率			接受特殊使用级抗菌药物前微生物标本送检率
方法	应送检例次	实送检例次	送检率	应送检例次	实送检例次	送检率	应送检例次	实送检例次	送检率
AMS干预前（2017年 1月~6月）	7 853	3 884	49.46%	6 204	2 967	47.82%	1 027	718	69.91%
AMS干预后（2017年 7月~12月）	8 164	5 057	61.94%	6 350	3 944	62.11%	743	620	83.45%
χ²值	252.96			258.83			42.79
P值	<0.001			<0.001			<0.001

科室	接受限制使用级抗菌药物送检率				接受特殊使用级抗菌药物送检率
科室	AMS干预前（%）	AMS干预后（%）	χ²值	P值	AMS干预前（%）	AMS干预后（%）	χ²值	P值
呼吸科	81.82	96.85	27.82	<0.001	95.56	97.15	2.05	0.152
儿科	79.62	97.28	38.79	<0.001	88.71	100.00	15.58	0.001
中心监护室	76.03	90.51	32.66	<0.001	74.45	92.12	45.75	<0.001
神经内科	35.87	72.12	48.25	<0.001	72.86	82.88	38.25	<0.001
心内科	28.72	51.80	58.59	<0.001	44.45	85.14	61.20	<0.001
普外科	18.38	45.22	103.96	<0.001	49.51	82.63	68.33	<0.001
神经外科	16.84	50.37	70.45	<0.001	42.81	80.87	165.27	<0.001
妇产科	9.41	36.81	62.02	<0.001	36.77	70.52	81.26	<0.001

标本种类	AMS干预前（2017年1月至6月）		AMS干预后（2017年7月至12月）		χ²值	P值
标本种类	标本例数	构成比	标本例数	构成比	χ²值	P值
呼吸道标本	7 601	53.46%	9 852	51.66%	10.53	0.001
血标本	1 700	11.96%	2 922	15.32%	77.21	<0.001
伤口脓液及分泌物	2 308	16.23%	2 321	12.17%	112.21	<0.001
尿液标本	1 374	9.66%	2 110	11.07%	31.44	<0.001
无菌体液	512	3.60%	787	4.10%	6.01	0.014
生殖道分泌物	6	0.04%	73	0.40%	39.91	<0.001
粪便	257	1.80%	365	1.90%	0.50	0.477
其他	460	3.20%	639	3.40%	0.67	0.414
合计	14 218	100%	19 069	100%